Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical Trial

NCT06620822 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

296

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: IBI363
DRUG: LM-108+Sintilimab
DRUG: IBI310+Sintilimab
DRUG: Sintilimab

Sponsor

Shanghai Pulmonary Hospital, Shanghai, China